Skip to main content

Table 4 Drug compliance and adverse events

From: New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study

 

Total (n = 109)

Drug compliance

 First 4 weeks compliance (%)

84.4 ± 21.2

 Second 4 weeks compliance (%)

91.6 ± 14.9

 Whole period compliance (%)

84.7 ± 21.2

Adverse events

 Dyspepsia (%)

10 (47.6)

 Diarrhea (%)

3 (14.3)

 Constipation (%)

3 (14.3)

 Vomiting (%)

2 (9.5)

 Skin rash (%)

2 (9.5)

 Leg cramps (%)

1 (4.8)

 Total adverse effects (n)

21

  1. Data are presented as mean ± standard deviation or number (percentage) of subjects
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us